A NOVEL APPROACHAND ADVANCEMENT IN RESPIRATORY DRUG DELIVERY SYSTEM

The respiratory drug delivery system (RDDS), which delivers drugs straight to the lungs for quicker effect and better bioavailability, is essential for treating respiratory disorders. It works particularly well for treating lung infections, COPD, and asthma. Metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and sophisticated aerosol formulations are examples of technology that are part of RDDS and maximize medication delivery to the lungs. Particle size, the drug’s physicochemical characteristics, and patterns of deposition within the respiratory system are some of the variables that affect how effective RDDS is. For example, smaller particles enhance therapeutic benefits by reaching deeper parts of the lungs. To ensure effective medication deposition while reducing adverse effects, the delivery system’s composition and design are essential. New developments in formulation science, nanotechnology, and inhaler design have propelled recent advances in RDDS. By improving treatment’s portability, accuracy, and convenience, these advancements are increasing patient adherence. Modern inhalers, for instance, provide improved particle accuracy and dosage control, increasing the treatment’s total efficacy. With its potential to revolutionize the treatment of respiratory disorders, RDDS is becoming more and more important in contemporary pharmacology. It is anticipated that RDDS will become increasingly more important in boosting patient care, improving treatment results, and transforming the management of respiratory diseases as long as technology developments continue.